- |||||||||| Keytruda (pembrolizumab) / Merck (MSD), Opdivo (nivolumab) / BMS
Review, Journal, PD(L)-1 Biomarker, IO biomarker: The role of PD-L1 expression in pituitary tumours: lessons from the current literature. (Pubmed Central) - Aug 7, 2024 PD-L1 positivity rates were significantly higher in proliferative pituitary tumours in comparison to non-proliferative tumours, but no differences were found concerning invasive or recurrent pituitary tumours. More studies following homogeneous and standardised methodologies are needed to fully elucidate the role and usefulness of PD-L1 expression in pituitary tumours.
- |||||||||| Opdivo (nivolumab) / BMS
Journal, Metastases: Nivolumab as a Promising Treatment Option for Metastatic Salivary Duct Carcinoma. (Pubmed Central) - Aug 7, 2024 After 57 cycles of nivolumab, the patient presents with partial remission and in good condition. We report, for the first time, a robust response of metastatic SDC to checkpoint inhibition with nivolumab without additional radiotherapy.
- |||||||||| Opdivo (nivolumab) / BMS, Yervoy (ipilimumab) / BMS
Journal, PD(L)-1 Biomarker, IO biomarker: Bronchiolitis after Combination Immunotherapy With Ipilimumab and Nivolumab in a Melanoma Patient. (Pubmed Central) - Aug 7, 2024 In our case, clinical and radiologic resolution was achieved after discontinuing the ICI and treatment with high-dose prednisone. This case shows that although bronchiolitis is a rare immune-related side effect of ICIs, oncologists, and pulmonologists should always be aware of this relatively easily treatable AE.
- |||||||||| Rituxan (rituximab) / Roche
Journal: Antibody surface mobility amplifies Fc?R signaling via Arp2/3 during phagocytosis. (Pubmed Central) - Aug 7, 2024 receptors (Fc?R) during antibody-dependent cellular phagocytosis...We conclude that on fluid surfaces, IgG-Fc?R microclustering promotes signaling through Syk that is amplified by Arp2/3 driven actin rearrangements. Thus, the surface mobility of antigens bound by IgG shapes the signaling of Fc?R with an unrecognized complexity beyond the zipper and trigger models of phagocytosis.
- |||||||||| Keytruda (pembrolizumab) / Merck (MSD), Opdivo (nivolumab) / BMS, Yervoy (ipilimumab) / BMS
Journal, Checkpoint inhibition, Tumor mutational burden, PD(L)-1 Biomarker, IO biomarker: Immune checkpoint inhibitors and the orbit; two cases of reactive dacryoadenitis. (Pubmed Central) - Aug 7, 2024 Furthermore, their efficacy appears to be greater in cancers with a high mutational burden. We present two female patients with bilateral reactive dacryoadenitis secondary to ICPi therapy, a finding that to the best of our knowledge was not previously described in the literature.
- |||||||||| Taltz (ixekizumab) / Eli Lilly, Japan Tobacco, Keytruda (pembrolizumab) / Merck (MSD)
Journal: Successful treatment of PD1-inhibitor induced psoriasiform dermatitis using IL-17 blockade without compromising immunotherapy efficacy. (Pubmed Central) - Aug 7, 2024 In three of the six cases, the patients exhibited clinical response to the primary malignancy after rechallenging with ICI, while remaining on an IL-17 inhibitor. Our case, in conjunction with the other reported cases, seems to suggest that IL-17 blockade can maintain a fine balance in this challenging clinical scenario by treating psoriasiform dermatitis without compromising the efficacy of immunotherapy.
- |||||||||| Rituxan (rituximab) / Roche
Journal: Shrinking Lung Syndrome: A Rare Pulmonary Complication of Systemic Lupus Erythematosus. (Pubmed Central) - Aug 7, 2024 A 38-year-old female recently diagnosed with SLE on hydroxychloroquine, prednisone, and methotrexate presented with a one-week history of progressive shortness of breath, non-productive cough, and pleuritic chest pain...Initial treatment included broad-spectrum antibiotics and intravenous methylprednisolone for a suspected lupus flare...Treatment often includes corticosteroids such as methylprednisolone and immunosuppressive agents. Rituximab has shown improvement in cases unresponsive to conventional therapy.
- |||||||||| Avastin (bevacizumab) / Roche, Tecentriq (atezolizumab) / Roche
Journal, Circulating tumor cells, PD(L)-1 Biomarker, Tumor cell: Changes of circulating tumor cells expressing CD90 and EpCAM in early-phase of atezolizumab and bevacizumab for hepatocellular carcinoma. (Pubmed Central) - Aug 7, 2024 The numbers and mean fluorescence intensity of the CTC subsets expressing CD90 and EpCAM molecules decreased in patients with partial response/stable disease, and increased in patients with progressive disease and were markedly correlated with overall survival. CD90(+) and EpCAM(+) CTCs may be candidate biomarkers for the early prediction of the treatment response and the overall survival of patients with HCC receiving Atezo-Bev therapy.
- |||||||||| Orencia (abatacept) / BMS
Journal: An efficient and successful outcome after haematopoietic stem cell transplantation in a patient with an LPS-responsive beige-like anchor gene mutation. (Pubmed Central) - Aug 7, 2024 Despite receiving abatacept therapy and immunoglobulin replacement treatments to manage the symptoms, but the symptoms still progressed...The patient experienced acute and chronic graft-versus-host disease (GVHD) and recurrent infections after transplantation. During one and a half years of follow-up, we found that allogeneic haematopoietic stem cell transplantation can relieve the symptoms of autoimmune disease in patients with LRBA deficiency, and marked clinical improvement and recovery of immune function were observed following stem cell transplantation.
- |||||||||| Keytruda (pembrolizumab) / Merck (MSD)
Journal: Pembrolizumab-induced myasthenia gravis: Two patients' experiences. (Pubmed Central) - Aug 7, 2024 The second patient is an 80-year-old woman with recurrent serous endometrial carcinoma who developed isolated ocular myasthenia after her second cycle of pembrolizumab. The symptoms and physical examination findings described here illustrate the breadth of symptom severity associated with pembrolizumab-induced MG and importance of early identification and treatment to minimize symptoms and improve outcomes.
- |||||||||| FT819 - Fate Therap, Memorial Sloan / Kettering Cancer Center
Enrollment change: FT819 in Moderate to Severe Active Systemic Lupus Erythematosus (clinicaltrials.gov) - Aug 7, 2024 P1, N=64, Recruiting, Recruiting --> Active, not recruiting | Phase classification: PN/A --> P2/3 | Trial primary completion date: Mar 2024 --> Jul 2025 N=32 --> 64
- |||||||||| Keytruda (pembrolizumab) / Merck (MSD), Lenvima (lenvatinib) / Eisai, Merck (MSD)
Biomarker, Enrollment closed, Combination therapy, Monotherapy, Tumor microenvironment, Immunomodulating: Pembrolizumab and Lenvatinib for the Treatment of Serous Ovarian Cancer Patients (clinicaltrials.gov) - Aug 7, 2024 P2, N=30, Active, not recruiting, Not yet recruiting --> Recruiting Recruiting --> Active, not recruiting
- |||||||||| AiRuiKang (dalpiciclib) / Jiangsu Hengrui Pharma, HRS-1358 / Jiangsu Hengrui Pharma
Enrollment status, Trial primary completion date, Monotherapy, Metastases: A Trial of HRS-1358 Tablets in Metastatic or Local Advanced Breast Cancer (clinicaltrials.gov) - Aug 7, 2024 P1, N=102, Recruiting, Trial completion date: Jan 2025 --> Jun 2025 Enrolling by invitation --> Recruiting | Trial primary completion date: Jun 2024 --> Dec 2024
- |||||||||| evalstotug (BA3071) / BeiGene
Trial completion date, Trial primary completion date, Combination therapy, Monotherapy: A Phase 1/2 Study of BA3071 in Patients With Solid Tumors (clinicaltrials.gov) - Aug 7, 2024 P1/2, N=320, Recruiting, Enrolling by invitation --> Recruiting | Trial primary completion date: Jun 2024 --> Dec 2024 Trial completion date: Jun 2025 --> Jun 2026 | Trial primary completion date: Dec 2024 --> Dec 2025
- |||||||||| Epkinly (epcoritamab-bysp) / Genmab, AbbVie
Trial primary completion date, Combination therapy: EPCORE DLBCL-2: A Study to Evaluate Change in Disease Activity of Subcutaneous (SC) Epcoritamab Combined With Intravenous and Oral Rituximab, Cyclophosphamide, Doxorubicin Hydrochloride, Vincristine, and Prednisone (R-CHOP) or R-CHOP in Adult Participants With Newly Diagnosed Diffuse Large B-Cell Lymphoma (DLBCL) (clinicaltrials.gov) - Aug 6, 2024 P3, N=900, Recruiting, Trial primary completion date: May 2037 --> Jan 2030 Trial primary completion date: Jan 2025 --> Aug 2026
- |||||||||| Adcetris (brentuximab vedotin) / Takeda, Pfizer
Clinical, Review, Journal, IO biomarker: How to treat localized Hodgkin lymphoma? (Pubmed Central) - Aug 6, 2024 Despite encouraging recent data, proof of their efficacy and safety on the longer term are still needed. Treatment decisions might be guided by new promising prognosis markers but their use in clinical practice is still to be determined.
- |||||||||| Adcetris (brentuximab vedotin) / Takeda, Pfizer
Journal: What is the best salvage therapy for Hodgkin lymphoma? (Pubmed Central) - Aug 6, 2024 Novel agents are now administered earlier in the disease course, resulting in higher cure rates. The focus of treatment is shifting towards achieving cure with minimal toxicity, reducing exposure to various agents, and advancing research in optimizing treatment sequencing and patient selection for less intensive therapies.
- |||||||||| Adcetris (brentuximab vedotin) / Takeda, Pfizer, Opdivo (nivolumab) / BMS
Journal: Treatment approaches for older Hodgkin lymphoma patients. (Pubmed Central) - Aug 6, 2024 The focus of treatment is shifting towards achieving cure with minimal toxicity, reducing exposure to various agents, and advancing research in optimizing treatment sequencing and patient selection for less intensive therapies. The increasing number of older HL patients constitutes a therapeutic challenge despite recent advances and the increased usage of targeted agents.
|